ÐÓ°ÉÔ­´´

Enterome's focus on immunomodulatory drugs positions it well in the health and biopharma sectors, particularly in cancer and immune diseases. Based in Paris and operating on a B2B model, the company leverages research in immune system modulation to develop treatments that may complement existing therapies like chemotherapy and immunotherapies. Its specialized approach offers a competitive edge, potentially leading to more effective treatments, faster recovery times, and improved survival rates. Backed by investors such as The Leukemia & Lymphoma Society’s Therapy Acceleration Program and Nestlé Health Science, Enterome shows strong market confidence and strategic support, enhancing its growth prospects in the biotech landscape.